Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.59M | 18.61M | 15.12M | 14.40M | 13.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.67M | 70.58M | 56.22M | 46.91M | 42.76M |
| Operating Income | -77.67M | -70.58M | -56.22M | -46.91M | -42.76M |
| Income Before Tax | -18.62M | -35.75M | -21.67M | -108.54M | -129.40M |
| Income Tax Expenses | 431.00K | 431.00K | -- | -- | -- |
| Earnings from Continuing Operations | -19.05 | -36.18 | -21.67 | -108.54 | -129.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.05M | -36.18M | -21.67M | -108.54M | -129.40M |
| EBIT | -77.67M | -70.58M | -56.22M | -46.91M | -42.76M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.23 | -0.93 | -1.34 | -2.72 | -4.86 |
| Normalized Basic EPS | -0.18 | -0.62 | -0.85 | -1.99 | -3.04 |
| EPS Diluted | -1.59 | -2.30 | -2.70 | -2.72 | -4.86 |
| Normalized Diluted EPS | -0.24 | -0.68 | -0.91 | -1.99 | -3.04 |
| Average Basic Shares Outstanding | 241.31M | 194.18M | 154.37M | 132.40M | 114.01M |
| Average Diluted Shares Outstanding | 244.84M | 197.71M | 157.90M | 132.40M | 114.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |